Klaus leads the clinical translation of Inhibrxâ€™s biotherapeutic pipeline. Prior to joining Inhibrx, Klaus trained at M.D. Anderson Cancer Center as a fellow and worked at Banner M.D. Anderson Cancer Center as a medical oncologist, where he also served as the local principal investigator of cancer immunotherapy trials. Klausâ€™s scientific work at Genentech and the Genomics Institute of the Novartis Research Foundation (GNF) focused on drug discovery and predictive biomarker development. Klaus received the highest academic honors and was a Scholar of the German Merit Foundation. He received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.